HRP20170484T1 - Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze - Google Patents

Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze Download PDF

Info

Publication number
HRP20170484T1
HRP20170484T1 HRP20170484TT HRP20170484T HRP20170484T1 HR P20170484 T1 HRP20170484 T1 HR P20170484T1 HR P20170484T T HRP20170484T T HR P20170484TT HR P20170484 T HRP20170484 T HR P20170484T HR P20170484 T1 HRP20170484 T1 HR P20170484T1
Authority
HR
Croatia
Prior art keywords
methyl
pyrazol
fluorophenyl
pyrrolo
dihydro
Prior art date
Application number
HRP20170484TT
Other languages
English (en)
Inventor
Todd W. Butler
Ramalakshmi Y. Chandrasekaran
Scot R. Mente
Chakrapani Subramanyam
Travis T. Wager
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20170484T1 publication Critical patent/HRP20170484T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Claims (13)

1. Spoj Formule I: [image] , naznačen time što: X je NR1, a navedeni R1 na N je C1-4 alkil ili C3-4cikloalkil; Y je CR1, a navedeni R1 na C je H ili CH3; prsten A je [image] , [image] ili [image] gdje je svaki R2 neovisno H, C1-6alkil, C4-10-bicikloalkil, -(CH2)t-CN, -SO2C1-6alkil, -SO2(CH2)t-C3-6cikloalkil, -C1-6alkil-O-C1-6alkil, -C1-6alkil-C(O)O-C1-6alkil, -C3-6cikloalkil-C(O)O-C1-6alkil, -C(O)-(O)u-C1-6alkil, -C(O)-C1-6alkil-O-C1-6alkil, -C(O)-(O)u-(CH2)t-(C6-10aril), -(CH2)t-(C6-10aril), -C(O)-(O)u-(CH2)t-(5- do 10-eročlani heteroaril), -(CH2)t-C(O)-NR5R6, -(CH2)t-(5- do 10-eročlani heteroaril), -C(O)-(O)u-(CH2)t-(3- do 10-eročlani heterocikloalkil), -(CH2)t-(4- do 10-eročlani heterocikloalkil), -C(O)-(O)u-(CH2)t-(3- do 10-eročlani cikloalkil) ili -(CH2)t-(3- do 10-eročlani cikloalkil), gdje navedeni aril, heteroaril, cikloalkil i heterocikloalkil u R2 može biti supstituiran s do dva supstituenta, koje se neovisno bira između halogena, OH, cijano, C1-6alkila, -C(O)-O-C1-3alkila ili C1-6alkil-O-C1-6alkila, i gdje bilo koji alkil, cikloalkil i heterocikloalkil u R2 može biti dodatno supstituiran s okso, gdje to valencija dopušta; svaki R4 je F; svaki R5 je neovisno H ili C1-6alkil; svaki R6 je neovisno H ili C1-6alkil; R7 je H; n je 0, 1 ili 2; svaki t je neovisno 0, 1 ili 2; i svaki u je neovisno 0 ili 1; ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što X je NR1, a navedeni R1 na N je C1-4alkil; svaki R2 je neovisno H, C1-6alkil, -SO2C1-6alkil, -SO2(CH2)t-C3-6cikloalkil, -C1-6alkil-O-C1-6alkil, -C(O)-(O)u-C1-6alkil, -(CH2)t-(C6-10aril), -C(O)-(O)u-(CH2)t-(5- do 10-eročlani heteroaril), -(CH2)t-C(O)-NR5R6, -(CH2)t-(5- do 10-eročlani heteroaril), -(CH2)t-(4- do 10-eročlani heterocikloalkil) ili -(CH2)t-(3- do 10-eročlani cikloalkil), gdje navedeni aril, heteroaril, cikloalkil i heterocikloalkil u R2 može biti supstituiran s do dva supstituenta, koje se neovisno bira između halogena, OH, cijano, C1-6alkila, -C(O)-O-C1-3alkila ili C1-6alkil-O-C1-6alkila, i gdje bilo koji alkil, cikloalkil i heterocikloalkil u R2 može biti dodatno supstituiran s okso, gdje to valencija dopušta; svaki R5 je H; n je 1; i Y, R4, R6, R7, t, u i A su definirani kao u patentnom zahtjevu 1.
3. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je R2 neovisno H, -CH3 ili SO2CH3.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj: 4-(3-(4-fluorfenil)-1-metil-1H-pirazol-4-il)furo[3,4-b]piridin-5(7H)-on; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-metil-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-benzil-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-(metilsulfonil)-6,7-dihidro-5H-pirolo[3,4-b]piridin; 6-(etilsulfonil)-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-propionil-6,7-dihidro-5H-pirolo[3,4-b]piridin; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-[(1-metil-1H-pirazol-4-il)metil]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-(tetrahidrofuran-3-ilmetil)-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-[(1,5-dimetil-1H-pirazol-3-il)metil]-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-ciklopentil-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-etil-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-[(1,5-dimetil-1H-pirazol-4-il)metil]-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-(ciklopropilmetil)-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-[2-(3-metil-1,2,4-oksadiazol-5-il)etil]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 3-{4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-5-okso-5,7-dihidro-6H-pirolo[3,4-b]piridin-6-il}propanonitril; 3-({4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-5-okso-5,7-dihidro-6H-pirolo[3,4-b]piridin-6-il}metil)benzonitril; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-[(1R,5S,6R)-3-oksabiciklo[3.1.0]heks-6-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-biciklo[1.1.1]pent-1-il-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-(piridin-3-ilmetil)-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; 6-(3-etoksipropil)-4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on; ili 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]-6-[(6-metilpiridin-3-il)metil]-6,7-dihidro-5H-pirolo[3,4-b]piridin-5-on.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]furo[3,4-b]piridin-5(7H)-on ili njegova farmaceutski prihvatljiva sol.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što je 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]furo[3,4-b]piridin-5(7H)-on.
7. Spoj u skladu s patentnim zahtjevom 5, naznačen time što je farmaceutski prihvatljiva sol of 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]furo[3,4-b]piridin-5(7H)-on.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja spavanja, te neurološke ili psihijatrijske bolesti ili poremećaja kod sisavca.
9. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je bolest ili poremećaj poremećaj raspoloženja ili poremećaj spavanja.
10. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se poremećaj raspoloženja bira iz skupine koju čine depresivni poremećaj i bipolarni poremećaj.
11. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je bolest ili poremećaj poremećaj nedostatka pažnje s hiperaktivnošću, shizofrenija ili Alzheimerova bolest.
12. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je bolest ili poremećaj Alzheimerova bolest.
13. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu podlogu.
HRP20170484TT 2010-12-20 2017-03-22 Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze HRP20170484T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061425213P 2010-12-20 2010-12-20
EP11805210.9A EP2654750B1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors
PCT/IB2011/055489 WO2012085721A1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20170484T1 true HRP20170484T1 (hr) 2017-06-02

Family

ID=45446116

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170484TT HRP20170484T1 (hr) 2010-12-20 2017-03-22 Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze
HRP20191469 HRP20191469T1 (hr) 2010-12-20 2019-08-14 Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinase

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20191469 HRP20191469T1 (hr) 2010-12-20 2019-08-14 Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinase

Country Status (24)

Country Link
US (1) US8536164B2 (hr)
EP (2) EP3181133B1 (hr)
JP (2) JP5684923B2 (hr)
KR (1) KR101590236B1 (hr)
CN (1) CN103260622B (hr)
AR (1) AR084412A1 (hr)
AU (1) AU2011346733C1 (hr)
CA (1) CA2819961C (hr)
CY (2) CY1118772T1 (hr)
DK (2) DK2654750T3 (hr)
ES (2) ES2623387T3 (hr)
HK (1) HK1188145A1 (hr)
HR (2) HRP20170484T1 (hr)
HU (2) HUE032405T2 (hr)
IL (1) IL226948A (hr)
LT (2) LT2654750T (hr)
MX (1) MX338551B (hr)
PL (2) PL2654750T3 (hr)
PT (2) PT3181133T (hr)
RS (2) RS59098B1 (hr)
SG (1) SG190802A1 (hr)
SI (2) SI3181133T1 (hr)
WO (1) WO2012085721A1 (hr)
ZA (1) ZA201303453B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2493876T1 (sl) * 2009-10-28 2014-04-30 Pfizer Inc. Derivati imidazola kot inhibitorji kazein-kinaze
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
EP2935272B1 (en) * 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
WO2015163446A1 (ja) * 2014-04-25 2015-10-29 協和発酵キリン株式会社 イミダゾール化合物の製造方法
JP2017222576A (ja) * 2014-10-31 2017-12-21 石原産業株式会社 有害生物防除剤
CN107365315B (zh) * 2016-05-11 2024-08-09 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co Ltd COMPOUNDS USED AS CASEIN KINASE INHIBITORS
CN115335057A (zh) * 2020-03-27 2022-11-11 北京原基华毅生物科技有限公司 抑制酪蛋白激酶的方法
CN111808102B (zh) * 2020-08-03 2021-12-31 南通大学 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法
AU2021342792A1 (en) * 2020-09-17 2023-06-01 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
KR20230069169A (ko) * 2020-09-17 2023-05-18 얀센 파마슈티카 엔.브이. 카제인 키나제 1 델타 조절제
WO2022115301A1 (en) * 2020-11-24 2022-06-02 Merck Sharp & Dohme Corp. Modified isoindolinones as glucosylceramide synthase inhibitors
WO2022127755A1 (en) * 2020-12-15 2022-06-23 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
WO2023241552A1 (en) * 2022-06-14 2023-12-21 Gritscience Biopharmaceuticals Co., Ltd Salt and/or crystal form for compounds as casein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
AU754830C (en) * 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
AU2728201A (en) * 1999-12-21 2001-07-03 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
KR20140026644A (ko) 2005-06-22 2014-03-05 케모센트릭스, 인크. 아자인다졸 화합물 및 사용방법
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
SI2493876T1 (sl) * 2009-10-28 2014-04-30 Pfizer Inc. Derivati imidazola kot inhibitorji kazein-kinaze

Also Published As

Publication number Publication date
AU2011346733B2 (en) 2015-08-13
CN103260622B (zh) 2015-05-13
RS55897B1 (sr) 2017-08-31
LT3181133T (lt) 2019-09-25
MX338551B (es) 2016-04-20
EP2654750B1 (en) 2017-03-08
PT3181133T (pt) 2019-09-16
JP5876596B2 (ja) 2016-03-02
HUE047089T2 (hu) 2020-04-28
SI2654750T1 (sl) 2017-04-26
EP2654750A1 (en) 2013-10-30
CA2819961A1 (en) 2012-06-28
WO2012085721A1 (en) 2012-06-28
KR101590236B1 (ko) 2016-01-29
ES2744099T3 (es) 2020-02-21
CN103260622A (zh) 2013-08-21
MX2013005833A (es) 2013-07-05
CY1122062T1 (el) 2020-11-25
EP3181133A1 (en) 2017-06-21
US8536164B2 (en) 2013-09-17
PL2654750T3 (pl) 2017-07-31
PL3181133T3 (pl) 2019-12-31
JP2015107992A (ja) 2015-06-11
ES2623387T3 (es) 2017-07-11
DK2654750T3 (en) 2017-05-01
SG190802A1 (en) 2013-07-31
CA2819961C (en) 2015-08-18
EP3181133B1 (en) 2019-07-24
AU2011346733A1 (en) 2013-07-18
IL226948A (en) 2017-04-30
HRP20191469T1 (hr) 2019-11-29
HUE032405T2 (en) 2017-09-28
ZA201303453B (en) 2014-07-30
AU2011346733C1 (en) 2015-12-24
AR084412A1 (es) 2013-05-15
HK1188145A1 (en) 2014-04-25
US20120157440A1 (en) 2012-06-21
SI3181133T1 (sl) 2019-10-30
DK3181133T3 (da) 2019-08-26
CY1118772T1 (el) 2017-07-12
JP5684923B2 (ja) 2015-03-18
RS59098B1 (sr) 2019-09-30
PT2654750T (pt) 2017-05-04
KR20130121126A (ko) 2013-11-05
LT2654750T (lt) 2017-05-10
JP2014503544A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
HRP20170484T1 (hr) Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze
JP6770127B2 (ja) Ｂｔｋ阻害薬としての一級カルボキサミド類
JP7505023B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
JP2014503544A5 (hr)
AU2010339423B9 (en) Therapeutic compounds and related methods of use
HRP20230086T1 (hr) Inhibitori lizin specifične demetilaze-1
HRP20190947T1 (hr) Heterociklički spoj
HRP20191163T1 (hr) Heteroaromatski spojevi i njihova upotreba kao dopaminskih liganda d1
JP2011527684A5 (hr)
WO2015025025A1 (en) Alkynyl alcohols and methods of use
FI3932919T3 (fi) Jak-inhibiittoriyhdiste ja sen käyttö
JP2014513139A5 (hr)
HRP20170349T1 (hr) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
JP2014522855A5 (hr)
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
JP2016504363A5 (hr)
JP2019530725A5 (hr)
TW201130852A (en) Novel thienopyrrole compounds
US11213520B2 (en) Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors
ES2902365T3 (es) Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
JP2018525377A5 (hr)
RU2019126033A (ru) Бициклические амины в качестве новых ингибиторов jak-киназы
JP7556604B2 (ja) トリアジン系化合物およびその組成物と用途
US20190308945A1 (en) Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
AR099529A1 (es) Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer